Pharmaceutica Analytica Acta

Department of Pharmacy, Southern University and A&M College, Baton Rouge, USA

Biography

Majumdar Zheng, is an influential researcher specializing in clinical pharmacology and epidemiology, with a focus on the long-term health impacts of diabetes and cardiovascular diseases. His work has made significant contributions to the understanding of drug safety, patient outcomes, and risk management in chronic conditions such as Type 2 diabetes.

Zheng is notably involved in the TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin), a clinical trial that investigates the cardiovascular outcomes of the drug Sitagliptin in diabetic patients. One of his key studies, Sitagliptin and Risk of Fractures in Type 2 Diabetes, published in Diabetes, Obesity and Metabolism (2017), examined the relationship between Sitagliptin use and the increased risk of fractures in patients with Type 2 diabetes?

His contributions extend to other areas of pharmaceutical research, especially focusing on how medications affect metabolic functions and the long-term health risks in diabetic patients. As a recognized expert, Zheng has collaborated with many leading institutions, contributing significantly to the clinical understanding of the safety profiles of medications for chronic diseases.

Publications

• Perspective Article   
  Role of Digital Therapeutics in Modern Healthcare: Revolutionizing Treatment Through Technology
  Author(s): Majumdar Zheng*
  
  

  DOI: 10.35248/2153-2435.24.15.781

  HTML PDF

Other relevant publications from this author

• 1. Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.